These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase. Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436 [TBL] [Abstract][Full Text] [Related]
3. [Pro-urokinase for infarct therapy]. Spiecker M; Meyer J Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689 [TBL] [Abstract][Full Text] [Related]
4. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. Tebbe U; Michels R; Adgey J; Boland J; Caspi A; Charbonnier B; Windeler J; Barth H; Groves R; Hopkins GR; Fennell W; Betriu A; Ruda M; Mlczoch J J Am Coll Cardiol; 1998 Mar; 31(3):487-93. PubMed ID: 9502624 [TBL] [Abstract][Full Text] [Related]
6. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437 [TBL] [Abstract][Full Text] [Related]
7. Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial. Spiecker M; Windeler J; Vermeer F; Michels R; Seabra-Gomes R; vom Dahl J; Kerber S; Verheugt FW; Westerhof PW; Bär FW; Nixdorff U; Barth H; Hopkins GR; von Fisenne MJ; Meyer J Am Heart J; 1999 Sep; 138(3 Pt 1):518-24. PubMed ID: 10467203 [TBL] [Abstract][Full Text] [Related]
8. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study. Vermeer F; Bösl I; Meyer J; Bär F; Charbonnier B; Windeler J; Barth H J Thromb Thrombolysis; 1999 Aug; 8(2):143-50. PubMed ID: 10436145 [TBL] [Abstract][Full Text] [Related]
10. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. The PRIMI Trial Study Group. Schofer J; Lins M; Mathey DG; Sheehan FH Eur Heart J; 1993 Jul; 14(7):958-63. PubMed ID: 8375422 [TBL] [Abstract][Full Text] [Related]
12. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949 [TBL] [Abstract][Full Text] [Related]
13. Saruplase versus other fibrinolytic agents. Michels HR Int J Clin Pract Suppl; 1998 Nov; 99():21-2. PubMed ID: 10344037 [No Abstract] [Full Text] [Related]
14. Pharmacology and clinical trial results of saruplase (scuPA) in acute myocardial infarction. Moser M; Bode C Expert Opin Investig Drugs; 1999 Mar; 8(3):329-35. PubMed ID: 15992082 [TBL] [Abstract][Full Text] [Related]
15. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246 [TBL] [Abstract][Full Text] [Related]
16. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Schneider J Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957 [TBL] [Abstract][Full Text] [Related]
17. Mode of action and pharmacology of saruplase. Vermeer F Int J Clin Pract Suppl; 1998 Nov; 99():6-8. PubMed ID: 10344034 [No Abstract] [Full Text] [Related]
18. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial. Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833 [TBL] [Abstract][Full Text] [Related]
19. [t-PA in thrombolytic therapy of acute myocardial infarct]. Rutsch W; Schmutzler H Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690 [TBL] [Abstract][Full Text] [Related]